Recent changes in the landscape of combination RAS blockade (Q37629835)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Recent changes in the landscape of combination RAS blockade	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Recent changes in the landscape of combination RAS blockade (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

author name string

Benjamin J Epstein

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Steven M Smith

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Rushab Choksi

3

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Expert Review of Cardiovascular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1373-1384

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Renin-angiotensin system and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Blocking the renin-angiotensin system: dual- versus mono-therapy

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Managing cardiovascular and renal risk: the potential of direct renin inhibition

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Renin inhibition in hypertension

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Plasma bradykinin in angio-oedema.

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

The angiotensin II type 2 receptor: what is its clinical significance?

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

The renin rise with aliskiren: it's simply stoichiometry

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Management of glomerular proteinuria: a commentary

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Review: renal protection by inhibition of the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Identifiers

10.1586/ERC.09.127

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37629835&oldid=1716478210"